Headquarters
SCHEELEVAGEN 27, LUND, LUND 223 63, SE
LUND, LUND, SE
CANTARGIA AB
From the company
Cantargia AB is a Swedish listed biotechnology company that develops antibody-based therapies targeting the IL1RAP molecule for the treatment of cancer as well as inflammatory and autoimmune diseases. The company has brought two candidate drugs into clinical development, nadunolimab (CAN04) and CAN10, and develops a preclinical project CAN14 derived from its CANxx antibody platform. Cantargia was founded in 2010 by researchers Thoas Fioretos, Marcus Järås and Kjell Sjöström based on research from Lund University, and is listed on Nasdaq Stockholm's Main
Products & services offered
Facilities
Send your requirements
Quantities, certifications, and timing.